FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents the use of sodium metaarsenite in preparing an oral dosage form of a pharmaceutical composition for inflammation treatment in a mammal.
EFFECT: use of sodium metaarsenite in preparing the oral dosage form of the pharmaceutical composition for inflammation treatment in a mammal.
6 cl, 7 ex, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF ARSENIC COMPOUNDS TO TREAT TISSUE OR ORGAN REJECTION | 2013 |
|
RU2665362C2 |
| USE OF ARSENIC COMPOUNDS FOR PAIN MANAGEMENT AND INFLAMMATION TREATMENT | 2008 |
|
RU2630574C2 |
| METHODS AND COMPOSITIONS FOR TREATING CANCER | 2009 |
|
RU2508116C2 |
| PHARMACEUTICAL COMPOSITION AND METHODS OF TREATING CANCER AND ITS METASTASES | 2006 |
|
RU2401662C2 |
| PHARMACEUTICAL COMPOSITION INCLUDING A HISTONE DEACETYLASE INHIBITOR AND METHOTREXATE | 2019 |
|
RU2772018C1 |
| NOVEL EFFICIENT INHIBITOR OF KINASE 4, ASSOCIATED WITH INTERLEUKIN-1 (IRAK4) | 2015 |
|
RU2613973C1 |
| EFFECTIVE METHOD OF USING DRUGS AND METHOD FOR PREVENTION OF BY-EFFECTS INTENSITY | 2005 |
|
RU2396982C2 |
| ORGANIC COMPOUNDS | 2007 |
|
RU2430921C2 |
| KINASE INHIBITORS | 2007 |
|
RU2440352C2 |
| 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE-METHYL, POLYMORPHOUS FORMS AND METHODS FOR USE THEREOF | 2014 |
|
RU2693833C2 |
